Recent Updates
Recently added Catalysts
BNTX

BioNTech Announces Commencement of Initial Public Offering

Tuesday, September 24, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BioNTech Announces Commencement of Initial Public Offering

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+16%
120-day peak, hindsight
Typical move
2.8%
average across 7 past catalysts
Lead asset
BNT162b2
Phase 3 · SARS-CoV-2 Infection

Full Press Release Details

BioNTech Announces Commencement of Initial Public Offering.
ShareAdd on Google
Tags: BNTX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 24, 2019

Biotech snapshot

Lead asset
BNT162b2Phase 3
SARS-CoV-2 Infection →

Catalyst track record

+16%
best trade around BNTX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for BNTX.

See every catalyst's timing & PoA →